U.S. FDA Accepts for Review the BLA for MenABCWY
U.S. FDA Accepts for Review the Biologics License Application (BLA) for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine candidate (MenABCWY). Pfizer submitted MenABCWY for the prevention of …
U.S. FDA Accepts for Review the BLA for MenABCWY Read More »
